Metagenomi Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Metagenomi Therapeutics, Inc. (MGX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$78.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$78.00K.
- Metagenomi Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$304.00K.
- Metagenomi Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$1.00K, a 100.05% decline year-over-year.
- Metagenomi Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$249.00K, a 2015.38% decline year-over-year.
- Metagenomi Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$449.00K, a 155.71% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $806.00K, a 355.37% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $177.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$78.00K 10-Q · filed 2026-08-10 | -$382.00K derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$304.00K 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | -$449.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$1.00K 10-Q · filed 2025-11-12 | -$250.00K derived: sum of 2 quarters · filed 2026-08-10 | -$338.00K derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$249.00K 10-Q · filed 2026-08-10 | -$337.00K derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$88.00K 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $806.00K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-12 | $1.92M derived: sum of 2 quarters · filed 2025-11-12 | $1.74M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $13.00K 10-Q · filed 2025-11-12 | -$168.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | -$181.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $177.00K 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $70.00 10-Q · filed 2024-11-13 | -$175.93K derived: sum of 2 quarters · filed 2024-11-13 | -$154.93K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$176.00K 10-Q · filed 2024-11-13 | -$155.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $21.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |